Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.33 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059880 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL841580 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL4062252 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL4067401 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL14380155 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL840549 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL4058133 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL4258623 | 0.98 | GNAI3 (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| Bromide SCHEMBL359338 | 0.98 | TSHR (0.35) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3245280 | 0.98 | GNAI3 (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9832998-B2 | Antiviral compositions | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-12-05 | — | — | US | disclosed |
| US-9832998-B2 | Antiviral compositions | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIV FLORIDA (US) | 2017-06-15 | — | — | US | disclosed |
| US-9549549-B2 | Antimicrobial materials and methods | STC.UNM (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150196032-A1 | ANTIVIRAL COMPOSITIONS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196032-A1 | ANTIVIRAL COMPOSITIONS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-07-16 | — | — | US | disclosed |
| US-8999316-B2 | Antiviral compounds | PACE UNIVERSITY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2209817-A1 | ANTIVIRAL COMPOSITIONS | Research Foundation of the City University of New York (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009040107-A2 | METHOD FOR THE PRODUCTION OF METAL-CONTAINING NANOPARTICLES | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041999-A1 | ANTIVIRAL COMPOSITIONS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009024312-A2 | METHOD FOR THE PRODUCTION AND STABILIZATION OF FUNCTIONAL METAL NANOPARTICLES IN IONIC LIQUIDS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2009-02-26 | — | — | WO | disclosed |
| US-20080299070-A1 | Antiviral Compounds | LONG ISLAND UNIVERSITY | 2008-12-04 | — | — | US | disclosed |
| US-20080299070-A1 | Antiviral Compounds | LONG ISLAND UNIVERSITY | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299070-A1 | Antiviral Compounds | EIF2AK2, MAVS, SARS1 | TSHR 4767/4885THRB 4880/4885GNAI3 1197/4885 |
| US-20150196032-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, MAVS, SARS1 | TSHR 4720/4885THRB 4882/4885GNAI3 1018/4885 |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | TSHR 3574/4885THRB 4033/4885GNAI3 3020/4885 |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | TSHR 3574/4885THRB 4033/4885GNAI3 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.